Growing potential of Chinese pharma highlighted amid call for investment

4 May 2016

An event next month is being billed as a chance to build on Chinese pharma’s potential as the country seeks foreign backers to make the most of its investment opportunities.

Organizers hope that CPhl China, taking place in Shanghai from June 21 to 23, will galvanize support for the industry, which is being backed by new government investment.

The government’s Made in China 2025 has listed biomedicine including gene therapies, monoclonal antibodies and vaccines as the priority for the industry in the future, though bringing these and other treatments to patients is likely to need foreign investment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK